Prana appoints US analyst to board
Thursday, 25 March, 2004
Melbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.
Most recently, Alsenas managed a hedge fund with an emphasis on biotechnology for ING Investment Management, New York.
"[Alsenas] is held in high regard in the international biotech sector and possesses an extensive knowledge of the industry in which Prana operates. Hi understanding of, and fundamental belief in, our technology and business strategy will help to shape Prana's future," said Prana CEO Geoffrey Kempler.
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
Why a gluten-free diet fails in some coeliac patients
Abnormal immune cells are driving ongoing intestinal inflammation that causes symptoms like...
Giving rotavirus vaccine at birth benefits gut bacteria
Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...
